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Background: Human cytomegalovirus (HCMV) is responsible for the most common intrauterine infections, which
may be acquired congenitally from infected pregnant woman to fetus. The research was aimed to estimate the role
of three single nucleotide polymorphisms (SNPs) located in TLR2 gene, and the common contribution of TLR2, and
previously studied TLR4 and TLR9 SNPs, to the occurrence of congenital HCMV infection in fetuses and newborns.
Methods: The study was performed in 20 Polish fetuses and newborns, congenitally infected with HCMV, and in 31
uninfected controls, as well as with participation of pregnant women, the mothers of 16 infected and 14 uninfected
offsprings. Genotypes in TLR2 SNPs were determined, using self-designed nested PCR-RFLP assays, and confirmed
by sequencing. The genotypes were tested for Hardy-Weinberg (H-W) equilibrium, and for their relationship with
the development of congenital cytomegaly, using a logistic regression model. The common influence of TLR2, TLR4
and TLR9 SNPs on the occurrence of congenital disease was estimated by multiple-SNP analysis.
Results: Distribution of the genotypes and alleles in TLR2 1350 T>C and 2029 C>T SNPs was similar between the studied
groups of fetuses and neonates. In case of 2258 G>A polymorphism, the GA heterozygotic status was significantly more
frequent in the infected cases than among the uninfected individuals (25.0% vs. 3.2%, respectively), and increased the risk
of HCMV infection (OR 10.00, 95% CI 1.07–93.44; P≤ 0.050). Similarly, the A allele within 2258 G>A polymorphism was
significantly more frequent among the infected offsprings than in the uninfected ones (12.5% vs. 1.6%; P≤ 0.050).
Complex AA variants for both TLR2 2258 and TLR9 2848 G>A polymorphisms, were estimated to be at increased risk of
congenital HCMV infection (OR 11.58, 95% CI 1.19–112.59; P≤ 0.050). Additionally, significant relationships were observed
between the occurrence of complex AA or GA variants for both TLR2 and TLR9 SNPs and the increased viral loads,
determined in fetal amniotic fluids and in maternal blood or urine specimens (P≤ 0.050).
Conclusions: Among various TLR2, TLR4 and TLR9 polymorphisms, TLR2 2258 G>A SNP seems to be an important factor
associated with increased risk of congenital HCMV infection in Polish fetuses and neonates.
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Human cytomegalovirus (HCMV) is responsible for the
most common intrauterine infections, transmitted with
urine, blood, saliva, genitourinary tract secretions, feces,
tears, transplanted organs, and by breastfeeding [1–5].
HCMV infections may be acquired congenitally through
vertical transmission of the virus by hematogenous
spread from infected pregnant woman to fetus via the
placenta or at the time of delivery, when the baby passes
through the birth canal [1].
In pregnant women, the seroprevalence rates of the in-
fections were reported to range from 40 to 100% [6–9].
Viral transmissions to the fetus are observed in approxi-
mately 30–40% of primarily infected pregnant women,
as well as in 1.1–1.7% of the patients with recurrent
infections [6–10]. During the first trimester of preg-
nancy, HCMV infections often result in severe congeni-
tal disease, although symptomatic cytomegaly was also
observed in the fetuses from pregnant women who
acquired HCMV infection during the third trimester of
pregnancy [11]. Severe symptoms, diagnosed in about 10
to 15% of congenitally infected neonates, include micro-
cephaly, ventriculomegaly, increased periventricular
echogenicity and calcifications [6, 9, 12]. Other symp-
toms, such as hearing impairment, visual impairment or
blindness, difficulties in learning and dyspraxia, observed
during the first months or in the first few years of life,
were determined in symptomatic congenital cytomegaly,
however, they may also occur in a condition, classified as
asymptomatic at birth [1, 6, 9].
Several studies reported some involvement of Toll-like
receptors (TLRs) in immune response against HCMV
[13–15]. Particularly, the TLR2 molecule was shown to
support the immunity to the virus [16–18]. In turn, a
study with HCMV permissive fibroblasts showed a func-
tional sensing of the virus by TLR2 through direct inter-
action with viral envelope glycoproteins (gp, g), gB and
gH [19]. In human acute monocytic leukemia cell line
THP1 and in foreskin fibroblast cell lines, HCMV infec-
tion induces the expression of TLR2, TLR3 and TLR9
genes [15, 18]. In colorectal cancer tissues, HCMV IE1-
72 protein expression correlates with TLR2 and TLR4
[20]. The upregulation of TLR2/4 mRNA expression,
beside increased levels of IL6 and TNF-α, as well as
reduced IL10 expression, were estimated in neutrophils
of venous blood samples obtained from pregnant women
with early-onset preeclampsia with hemolysis, elevated
liver enzymes and low platelets syndrome that had
significantly higher anti-HCMV IgG seropositivity, as
compared to non-pregnancy controls [21]. In platelets,
extracted from healthy donors, a purified clinical HCMV
isolate VR1814 bound the TLR2 molecule, and activated
signal transduction, degranulation and release of CD40
IL1β and VEGF [22]. The involvement of TLR2, as wellas of IFN-β, in the response to HCMV, was also reported
for NK cells [17].
Taking into account genetic modifications, the single
nucleotide polymorphisms (SNPs) located within TLR2
gene, were reported to be correlated with HCMV infec-
tions as well [23–25]. In children with congenital HCMV
disease, the CC genotype in TLR2 1350 T>C SNP
(rs3804100) was associated with the infection, although
no relationship was established with the course of cyto-
megaly [25]. In liver transplant recipients, the homozy-
gotic status in TLR2 2258 G>A SNP (rs5743708) was
associated with HCMV disease, especially tissue-invasive
disease [24]. In another study, also performed in liver
transplant recipients, significantly higher viral loads were
observed among the patients, either with the minor
alleles or being heterozygotes in TLR2 2258 G>A poly-
morphic site, as compared to wild type homozygotes
[26]. An in vitro study with transfected HEK293 cells
showed some involvement of TLR2 2258 G>A SNP in
the TLR2 signaling pathway after exposure to viral gB
protein [23]. Therefore, the analyzed polymorphism was
suggested to participate in the development of HCMV
disease in humans [23]. Other studies also showed the
SNPs located in TLR2, as well as in TLR3, TLR4, TLR7
and TLR9 genes, to be contributing to HCMV infection
[13, 14, 27]. So far, no study has shown any relationship
between genetic alterations in TLR2 2258 G>A SNP
and congenital HCMV infection. Several studies had
previously been performed to investigate the role of
this polymorphism in pregnancy disorders, including
preeclampsia, bacterial vaginosis, and preterm birth
[28–31]. Moreover, the GA heterozygosity within TLR2
2258 polymorphism was shown to be involved in tuber-
culosis among Turkish children, as well as Candida
sepsis in German adult patients [32, 33].
We previously reported a possible contribution of
TLR4 and TLR9 SNPs to congenital cytomegaly [14].
These recently published outcomes, as well as the avail-
able literature data on the contribution of TLR2 SNPs to
the occurrence of HCMV infection, prompted us to
undertake further research, evaluating the role of TLR2
1350 T>C coding synonymous (Ser450, rs3804100), as
well as 2029 C>T (Arg677Trp, rs121917864) and 2258
G>A non-synonymous (Arg753Gln) SNPs in the devel-
opment of HCMV congenital infection in fetuses and ne-
onates. Moreover, the common influence of TLR2 2258
G>A, as well as of the recently studied TLR4 896 A>G,
1196 C>T and TLR9 2848 G>A SNPs [14] on the occur-
rence of the infection and on congenital cytomegaly de-
velopment was also estimated. The distribution of
genotypes and alleles in TLR4 and TLR9 polymorphisms,
and of the haplotypes for TLR4 SNPs, between the
analyzed groups of the offsprings, was reported in our
previous paper [14].
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The reported study included 20 fetuses and neonates
on the day of birth, congenitally infected with HCMV,
and 31 control cases without infection. In the analyzed
population of infected offsprings, 35.0% (7/20) were fe-
tuses and 65.0% (13/20) - neonates. Among the studied
patients, 18 HCMV infected fetuses and neonates, as
well as 20 control individuals, were previously investi-
gated regarding TLR4 and TLR9 SNPs [14]. Consider-
ing pregnant women, the mothers of 16 infected
fetuses and neonates, and of 14 uninfected offsprings,
were also enrolled into the reported study, based on
the availability of clinical samples. Fetal, neonatal, and
maternal specimens were retrospectively, randomly
collected at the Department of Fetal-Maternal Medi-
cine and Gynecology of the Polish Mother’s Memorial
Hospital - Research Institute (PMMHRI) in Lodz
between the years 2000 and 2013. Among the infected
offsprings, eleven (11) presented symptomatic cytome-
galy, while nine (9) were asymptomatic. The ultra-
sound markers, associated with symptomatic disease
consisted of ventriculomegaly, hydrocephaly and fetal
hydrops, as well as demonstrated intrauterine growth
restriction (IUGR), ascites, pericardial effusion, cardio-
megaly and hyperechogenic foci in various organs. In
turn, asymptomatic cytomegaly was determined in fe-
tuses and newborns without any ultrasound symptoms,
which could have been related to the disease. The ma-
terials, classified for genetic studies, included amniotic
and/or ascitic (two samples) fluids, umbilical cord
blood and amniotic membranes, as well as whole
blood, plasma, serum and urine samples from new-
borns. The fetal amniotic fluid samples were obtained
via amniocentesis in pregnant women, treated at the
Institute. The umbilical cord blood samples and mem-
branes of fetuses, as well as neonate blood and urine
samples were collected on the day of birth. A prelimin-
ary diagnosis of intrauterine HCMV infection was based on
the maternal serological status and fetal and neonatal
cytomegaly-related ultrasound markers. HCMV DNA find-
ing in, at least, one of the available examined clinical mate-
rials obtained from a single patient, was the confirmation of
congenital infection. Both detection and quantitation of
HCMV DNA, was also performed for 75.0% (15/20)
of mothers of the infected offsprings. In case of preg-
nant women, whole blood, serum or urine samples
were used to determine the presence and the levels of
viral DNA. The study was approved by the Research
Ethics Committee at the PMMHRI. The clinical sam-
ples, used in the study, were previously collected and
anonymized. Informed consent forms were signed by
the pregnant women, participating in the study, and
the consent procedure was accepted by the Research
Ethics Committee.Serological tests
Blood specimens were collected from randomly selected
pregnant women by venipuncture during their first visit to
the Institute. Serum samples were obtained by centrifuga-
tion and then stored at 4 °C before analysis, on the day of
blood collection. Serological tests were performed at the
Department of Clinical Microbiology at the Institute.
Screening for anti-HCMV antibodies was performed
with Eti-Cytok G-Plus and Eti-Cytok M-Reverse Plus
tests (Diasorin/Biomedica, Italy), between the years 2000
and 2001, VIDAS CMV IgG and IgM tests (bioMérieux,
France) – between 2001 and 2006, anti-CMV IgG and
IgM tests (Diasorin/Biomedica, Italy) – between 2006
and 2011 years, and ELFA assays – from the year 2012.
HCMV infection was determined in pregnant women in
case of IgG seroconversion during pregnancy in the
presence of IgG and IgM specific antibodies or a low
IgG avidity index. Active viral infection was determined
in the pregnant women, as well as in their fetuses and
neonates, using real-time Q PCR assays for viral UL55
gene in blood, urine and amniotic fluids.
DNA isolation
Genomic and/or viral DNA was extracted from 5 ml of
the amniotic fluid, 3 ml of the ascitic fluid, 200 μl of um-
bilical cord blood, neonatal whole blood, plasma or
serum specimens, from fetal membranes and 5 ml of
neonatal urine specimens, as well as from maternal
whole blood, serum or urine samples, using a QIAamp
DNA Mini Kit (QIAGEN, Hilden, Germany). The
extracted DNA was diluted in 100 μl of elution buffer
and stored at −20 °C until molecular analyses.
Detection and quantification of HCMV DNA
HCMV DNA was identified and quantified by a real-
time Q PCR assay of a viral UL55 gene fragment of
150 bps in length, as previously described [34, 35].
Standard curves, used in the quantitative analyses, were
plotted with serial 10-fold dilutions from 105 to 1 plas-
mid DNA, containing the entire HCMV UL55 open
reading frame [36]. The real-time Q PCR assays were
performed, using a 7900 HT Fast Real-Time PCR System
(Applied Biosystems, USA).
Determination of SNPs located within TLR2 gene
Nested PCR assays were developed to determine the geno-
typic status in TLR2 1350 T>C, 2029 C>T, and 2258 G>A
polymorphic sites. The GenBank accession numbers for the
coding sequences, as well as the sequences of external and
internal primers, amplicon lengths and annealing tempera-
tures, used in nested PCRs, are shown in Table 1. The
external primers were designed, using the Vector NTI Suite
5.5 software, whereas the internal primers were taken from
published articles [37–40]. Nested PCR assays were
Table 1 Primers, annealing temperatures and amplicons used in PCR assays for SNPs in the TLR2 gene
Gene GenBank
accession no.a




TLR2 NC_000004.12 1350 T>C External For: AATTCAGCCTGTGAGGATGC 52 361
(rs3804100) Rev: GTAAGAGGGAGGCATCTGGTA
(Ser450) Internal For: TCATTTGGCATCATTGGAAA 55 248
(S450) Rev: GAGTTGCGGCAAATTCAAAG
2029 C>T; 2258 G>A External For: CGGAATGTCACAGGACAGC 52 605
(rs121917864; rs5743708) Rev: GGACTTTATCGCAGCTCTCAG
(Arg677Trp; Arg753Gln) Internal For: GCCTACTGGGTGGAGAACCT 59 340
(R677W; R753Q) Rev: GGCCACTCCAGGTAGGTCTT
aNo. number
bSNP single nucleotide polymorphism
cbps base pairs
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Hilden, Germany). The amplification conditions were as
follows: an initial, 15-min activation at 95 °C and 40 cycles
of repeated denaturation at 94 °C for 30 s, annealing at 52 °
C (for external primers) or 55 °C/59 °C (for internal primers
encompassing 1350 T>C/ 2029 C>T and 2258 G>A SNPs,
respectively) for 1 min and extension at 72 °C for 2 min
and the final extension at 72 °C for 10 min. The nested
PCR products for TLR2 1350 T>C, or 2029 C>T and 2258
G>A SNPs, were resolved by electrophoresis on 1% agarose
gels and then digested with MwoI or AciI endonucleases,
respectively. Restriction reaction mixtures consisted of
10 μl of the PCR product, 10 U of endonuclease, 1 x con-
centrated buffer for the enzyme and distilled nuclease-free
water, added to the final reaction volume of 20 μl. The
digestions were performed overnight at 37 °C, and then the
MwoI or AciI enzymes were inactivated by incubation for
20 min at 80 °C or 65 °C, respectively, following the restric-
tion reaction. The obtained restriction products were
resolved on 2% agarose gels. The genotypes in TLR2 poly-
morphic sites were determined for all the analyzed samples,
based on the length of restriction fragments ([37–39], see
Table 2, Fig. 1). The genotypes were studied at the ScientificTable 2 Lengths of restriction fragments and genotypic profiles
TLR2 SNPa Restriction enzyme Profile (bps)b
1350T>C MwoI TT: 248
TC: 248, 164, 84
CC: 164, 84
2029 C>T AciI CC: 227, 75, 38
CT: 302, 227, 75, 38
TT: 302, 38
2258 G>A AciI GG: 227, 75, 38
GA: 227, 265, 75, 38
AA: 265, 75
aSNP single nucleotide polymorphism
bbps base pairsLaboratory of the Center of Medical Laboratory Diag-
nostics and Screening. The randomly selected PCR
products, representative for six TT homozygotes and
one TC heterozygote in TLR2 1350 T>C polymorphism,
for 39 CC homozygotes in 2029 C>T locus, as well as
for 33 GG homozygotes and six GA heterozygotes in
2258 G>A SNP, were confirmed by sequencing by the
Sanger method at the Genomed Joint-Stock Company
(Warsaw, Poland). The exemplary chromatograms with
fragments of DNA sequences for both kinds of deter-
mined genotypes in the analyzed polymorphic sites are
presented in Fig. 2. The sequenced and the reference
fragments of TLR2 gene were compared, using the
BLASTN program and the chromatograms were
analyzed, using the Sequence Scanner 1.0 (Applied
Biosystems) software.
Statistical analysis
The prevalence rates of genotypes and alleles in TLR2
2258 G>A SNP were calculated, both in the HCMV
infected and uninfected fetuses and neonates by
means of descriptive statistics. The offsprings were
studied for the Hardy-Weinberg (H-W) equilibrium,
using the SNPStats software (http://bioinfo.iconcolo
gia.net/en/SNPStats_web). The applied test compares
the observed and expected allele prevalence rates
under the assumption of independence, as well as es-
timates a Chi-squared distribution with one degree of
freedom. A relationship was determined between the
genetic modifications in TLR2 polymorphism and the
development of congenital HCMV infection, using
cross-tabulation, Pearson’s Chi-squared and Fisher’s
exact tests, as well as the logistic regression model.
An association was estimated, based on multiple-SNP ana-
lysis by the Expectation Maximization (EM) algorithm,
between the genetic status within TLR2 2258 G>A, as well
as in previously studied TLR4 896 A>G, 1196 C>T and
TLR9 2848 G>A SNPs [14] and the occurrence of HCMV
Fig. 1 PCR-RFLP profiles for TLR2 1350 T>C (a), and 2029 C>T and 2258 G>A (b) SNPs. RFLP products were separated in 2% agarose gels, stained
with ethidium bromide. The numbers on the right side of electropherograms show the lengths of resolved DNA fragments. M – 50 bp DNA
marker; Ud – undigested PCR product; CC, GG, GA, TC, and TT – genotypes in analyzed TLR2 SNPs
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linear regression model was used to calculate a correlation
of the fetal and neonatal genotypic status in TLR2 2258
G>A polymorphism with HCMV DNA levels in body
fluids of the studied offsprings or their mothers. All the
results were defined as statistically significant, when
attained the significance level of P ≤ 0.050. A part of the
statistical analysis of the distribution of identified alleles




In the fetuses and newborns, which were either congeni-
tally HCMV infected or uninfected, the genotypes in
TLR2 2258 G>A polymorphism preserved the H-W
equilibrium (P = 1.000).
HCMV DNA loads in fetal, neonatal and maternal body
fluids
The median load of HCMV DNA in whole blood speci-
mens of the infected offsprings was 5.9 × 103 copies/ml
and ranged from 1.6 × 102 to 2.0 × 106 copies/ml, while
the mean viral load was 2.8 × 105 copies/ml. Regarding
amniotic fluid samples, the median HCMV DNA load
was 1.5 × 103 copies/ml, ranging from 2.2 × 102 to 4.3 ×
106 copies/ml, and the mean viral load was 6.7 × 105
copies/ml. In case of ascitic fluids, the median and mean
viral loads were 3.4 × 103 copies/ml, and ranged from
1.5 × 102 to 6.7 × 103 copies/ml. HCMV DNA load deter-
mined for plasma specimen was 2.1 × 102 copies/ml, and
for urine samples – 9.3 × 105 copies/ml. In pregnant
women, the median viral load in whole blood specimens
was 6.3 × 102 copies/ml and the mean viral load was
4.1 × 103 copies/ml. In urine samples, median HCMVload was 4.3 × 102 copies/ml and mean load was 9.3 ×
102 copies/ml. In case of plasma samples, the median
and mean HCMV loads were 3.5 × 102 copies/ml, while
the serum viral load was 3.6 × 103 copies/ml.
Prevalence rates of the genotypes in TLR2 1350 T>C, 2029
C>T and 2258 G>A SNPs
Genotypes in TLR2 1350 T>C, 2029 C>T, and 2258
G>A SNPs, were successfully determined for all DNA
samples obtained from fetuses and newborns selected
for genetic tests. In case of TLR2 1350 T>C SNP, only
one uninfected fetus carried TC heterozygotic status,
while all other fetuses and newborns were TT homozy-
gotes. In the range of TLR2 2029 C>T polymorphism, all
the studied offsprings were CC homozygotes. Consider-
ing TLR2 2258 G>A SNP, the prevalence rates of GG
and GA genotypes were 75.0% (15/20) and 25.0% (5/20),
respectively (see Table 3A). In case of the uninfected con-
trol offsprings, the prevalence rates of GG and GA geno-
types in TLR2 SNP were 96.8% (30/31) and 3.2% (1/31),
respectively. The GA heterozygotic status in the SNP, was
significantly more frequent among the infected than the
uninfected cases (25.0% vs. 3.2%, respectively), and in-
creased the risk of HCMV infection (OR 10.00, 95% CI
1.07–93.44; P ≤ 0.050). Among the patients with symptom-
atic cytomegaly, the prevalence rates of GG and GA
genotypes were 81.8% (9/11) and 18.2% (2/11), respectively
(see Table 3B). In case of asymptomatic disease, the GG
and GA genotype carriers were identified in 66.7% (6/9)
and 33.3% (3/9) of cases, respectively. Regarding the con-
genital cytomegaly outcome, similar prevalence rates of the
genotypes were observed in the infected offsprings with
symptomatic and asymptomatic disease. Among the preg-
nant women, being mothers of both HCMV infected and
uninfected fetuses and neonates, only one mother of the
Fig. 2 Chromatograms comprising TLR2 1350 T>C (a, b), 2029 C>T (c), and 2258 G>A (d, e). The genotypes in TLR2 SNPs were determined for the
forward strand sequences. CC, GG, GA, TC, and TT – genotypes in described SNPs
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ORb (95% CI)c P-valued
Infected cases Controls
GG 15 (75.0%) 30 (96.8%) 1.00 0.018









GG 9 (81.8%) 6 (66.7%) 1.00 0.440
GA 2 (18.2%) 3 (33.3%) 0.44 (0.06–3.51)
The prevalence rates of genotypes in TLR2 SNP were compared between infected and uninfected fetuses and newborns (A) as well as symptomatic and
asymptomatic offsprings with congenital cytomegaly (B)
P ≤ 0.050 is considered as significant
an number of tested fetuses and newborns
bOR odds ratio
c95% CI, confidence interval
dlogistic regression model
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status in TLR2 2258 G>A locus, while all other studied
women demonstrated GG homozygotes within this
polymorphism. Taking into account the outcomes for
TLR2 2258 G>A SNP, obtained in the current study,
as well as for TLR4 896 A>G, 1196 C>T and TLR9
2848 G>A SNPs, reported in our previous paper [14],
the additional multiple-SNP analysis showed the oc-
currence of complex AA variants in the range of both
TLR2 and TLR9 polymorphisms to be correlated with an
increased risk of HCMV infection among studied fetuses
and neonates (OR 11.58, 95% CI 1.19–112.59; P ≤ 0.050,
see Table 4). In case of other multiple-SNP variants, a
similar distribution pattern was observed between the in-
fected and uninfected fetuses and neonates. Moreover, theTable 4 Multiple-SNP variants for TLR2, TLR4 and TLR9 polymorphism
TLR gene’s polymorphisms Multiple-
SNPa
variant
Prevalence rates of mu
Infected cases
TLR2 2258 G>A – TLR4 896 C>T GA 0.850
GG 0.025
AA 0.125
TLR2 2258 G>A – TLR4 1196 C>T GC 0.875
AC 0.125
TLR2 2258 G>A – TLR9 2848 G>A GA 0.400
GG 0.475
AA 0.125
P ≤ 0.050 is considered as significant
aSNPs single nucleotide polymorphisms
bOR odds ratio
c95% CI confidence interval
dlogistic regression modeldistribution of all the multiple-SNP variants, determined
between the infected offsprings with both symptomatic
and asymptomatic cytomegaly was also similar.
Prevalence rates of the alleles in TLR2 2258 G>A
polymorphism
In HCMV infected fetuses and neonates, the preva-
lence rates of G and A alleles in TLR2 2258 G>A
SNP, were 87.5% (35/40) and 12.5% (5/40), respect-
ively (see Table 5A). Among the uninfected control
cases, the corresponding values of G and A alleles were
98.4% (61/62) and 1.6% (1/62), respectively. The A allele
was significantly more frequently observed among the in-
fected offsprings, when compared to the uninfected ones
(12.5% vs. 1.6%; P ≤ 0.050; Fisher’s exact test). Among thes and the occurrence of congenital HCMV infection
ltiple-SNP variants ORb (95% CIc) P-valued
Uninfected controls
0.874 1.00
0.109 0.39 (0.06–2.59) 0.330
0.016 8.81 (0.93–83.12) 0.063
0.859 1.00
0.016 8.03 (0.85–75.63) 0.075
0.576 1.00
0.408 1.62 (0.58–4.53) 0.360
0.016 11.58 (1.19–112.59) 0.040
Table 5 Distribution of the alleles, located in TLR2 2258 G>A polymorphic site
A.
Gene polymorphism and allele No.a of carriers with TLR2 alleles (%) P-value
Infected cases Controls
TLR2 2258 G>A
G 35 (87.5) 61 (98.4) 0.033b
A 5 (12.5) 1 (1.6)
B.
Gene polymorphism and allele No.a of carriers with TLR2 alleles (%) P-value
Symptomatic cases Asymptomatic cases
TLR2 2258 G>A
G 20 (90.9) 15 (83.3) 0.471c
A 2 (9.1) 3 (16.7)
The prevalence rates of alleles in TLR2 SNP were compared between infected and uninfected fetuses and newborns (A) as well as between symptomatic and
asymptomatic offsprings with congenital cytomegaly (B)
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alleles were 90.9% (20/22) and 9.1% (2/22), respectively
(see Table 5B). In case of the asymptomatic disease, the
corresponding values of G and A alleles were 83.3%
(15/18) and 16.7% (3/18), respectively. Similar preva-
lence rates of the alleles were observed in the symp-
tomatic and the asymptomatic cases (P = 0.471;
Pearson’s Chi-squared test).
Relationship between genotypes in TLR2 2258G>A SNP
and HCMV DNA load
In the fetuses and neonates, the genotypic status within
TLR2 2258 G>A SNP was not associated with HCMV
DNA loads, determined both in whole blood and amni-
otic fluid samples (P = 0.460 and P = 0.250, respectively).
Among the infected offsprings, the GA heterozygotes
tended to be correlated with higher viral loads in whole
blood and urine samples of their mothers (mean differ-
ence (MD) 1.1 × 104 copies/ml; P = 0.180 and P = 0.200,
respectively). Multiple-SNP analysis showed GA complex
variants in the range of TLR2 2258 and TLR9 2848 G>A
SNPs to be correlated with higher viral loads, determined
in fetal amniotic fluids and maternal urine samples (MD
1.2 × 106 and 1.1 × 104 copies/ml, respectively, P ≤ 0.050).
In case of AA multiple-SNP variants for the studied TLR2
and TLR9 SNPs, significantly higher viral loads were esti-
mated in maternal blood and urine specimens (MD 8.5 ×
104 and 1.5 × 104 copies/ml, respectively, P ≤ 0.050).
Discussion
In the reported study, the GA heterozygotic status in
TLR2 2258 G>A SNP was found to be correlated with
HCMV congenital infection in Polish fetuses andnewborns. The identified heterozygotes in the range of
TLR2 SNP were estimated as 10 times more susceptible to
develop the infection. TLR2 molecule was previously re-
ported to be involved in the immune response against
HCMV [15, 19–21]. In ectocervical tissue, HCMV infec-
tion was blocked by ligands for TLR2 (LTA), as well as
TLR9 (CpG) molecules [41]. In HCMV infected human
permissive fibroblasts, the TLR2 molecule was reported to
have been involved in NF-κB activation and inflammatory
cytokine secretion, but not in IFN signaling [16]. In turn,
the TLR2 molecule of murine monocytes was shown to be
involved in the production of IFN-β, observed after stimu-
lation with murine cytomegalovirus (MCMV) or vaccinia
virus [VV; [41]). TLR2 knock-out mice were reported to
have impaired NK cell function and elevated MCMV load
[42]. The TLR2 molecule was also observed as involved in
the immune response to other viruses, such as varicella
zoster virus (VZV), Epstein-Barr virus (EBV) and murine
respiratory syncytial virus (RSV), as well as hepatitis B and
C viruses [43–47].
Taking into account genetic modifications within the
TLR2 gene, previous studies also reported contribution of
TLR2 2258 G>A coding non-synonymous SNP to HCMV
infection, although the mutated homozygotes were found
in some studied populations only [23, 24, 26]. In a cohort
of liver transplant recipients treated at the Mayo Clinic,
Minnesota, United States, some relationship was deter-
mined between homozygosity in the analyzed TLR2 poly-
morphism and HCMV infection, especially in tissue-
invasive disease [24]. An in vitro study of the transfected
human embryonic kidney (HEK) 293 cells, that were ex-
posed to HCMV gB, showed TLR2 2258 SNP to have been
involved in TLR2 signaling impairment [23]. Another
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chronic hepatitis C, treated also at the Mayo Clinic,
showed a certain association of TLR2 polymorphism with
HCMV load [26]. The homozygotic status in the analyzed
SNP was correlated with cytomegaly, as well as with an in-
creased risk for the disease after adjusting for patienťs age,
HCMV serostatus and allograft rejection [26]. Taking into
account our results and the previous literature data, TLR2
2258 G>A SNP may be involved in congenital infection
with HCMV in Polish fetuses and neonates. Considering
HCMV DNA loads determined in fetal and neonatal body
fluids, no association was observed with genotypic vari-
ability within the analyzed polymorhism. Before our study,
no attempt had been reported to investigate the function
of TLR2 2258 G>A polymorphism in congenital infection
with HCMV. A study performed in 88 infants and 63
adults infected postnatally with HCMV, and in 28 healthy
neonates and 50 healthy adults, may suggest a possible
protective role of CT heterozygotic status in TLR2 2029
C>T locus against the infection development among adult
patients [13]. However, similarly to our outcomes, the
mentioned study showed that all the analyzed infants were
CC homozygotes in the range of 2029 C>T polymorphism
[13]. Additionally, we also found the same distribution of
genotypes within TLR2 1350 T>C SNP among both
HCMV infected and uninfected fetuses and neonates, al-
though the polymorphism was reported to be signifi-
cantly associated with congenital cytomegaly among
Japanese children [25]. Since the C allele in TLR2 1350
T>C SNP is more frequent among the Japanese than in
the European populations (25.48% vs. 6.36%, see http://
www.ncbi.nlm.nih.gov/variation/tools/1000genomes/?q
=rs3804100), the geographical origin might be the
major reason of differential role of the analyzed poly-
morphism in susceptibility to congenital infection with
HCMV. It seems that further studies with larger groups
of patients, congenitally infected with the virus, would
be an interesting challenge. Considering TLR2 2258
G>A SNP, the individual cases of GA heterozygotes and
AA recessive homozygotes were observed among
HCMV infected infants, and not among the uninfected
offsprings [13]. Similarly, in our study, the prevalence
rate of the minor allele in TLR2 2258 G>A locus was
higher among the HCMV infected infants than in the
uninfected ones. Moreover, the paper by Jabłońska
et al. reported the occurrence of AA homozygotes
among the infected adults, but not among uninfected
patients [13]. The GA heterozygotes were not found
among non-HCMV infected infants [13]. In our study, we
observed minor alleles in TLR2 2258 SNP only as heterozy-
gotes, whereas no AA homozygotes were found. It should
be emphasized that in our reported study, we evaluated fe-
tuses and neonates on the day of birth, with congenital
HCMV infection. In contrast, Jabłońska et al. exploredinfants, aged 1–12 months, with postnatal HCMV infec-
tion, qualified by clinical symptoms or evidence of the
infection confirmed by viral DNA detection in whole
blood/urine samples after 3 weeks of life, and by the pres-
ence of HCMV-specific antibodies [13]. It is possible that
the obtained results are different, since the two different
groups of patients were examined. Additionally, the preva-
lence rates of genotypes and alleles, located within the ana-
lyzed TLR2 polymorphisms, as well as their associations
with the occurrence of congenital HCMV infection, esti-
mated in the current research, might have been due to the
small sample size cohort of the studied offsprings. Likewise
to our results, the prevalence rates of A allele in TLR2 2258
G>A SNP was determined to be low and a lack of AA ho-
mozygotes was also reported in other study groups, such as
German, Finnish and Caucasian adults, or Turkish children
[32, 48–50]. The heterozygotic status and A allele in TLR2
2258 G>A polymorphism were significantly more fre-
quently identified among Turkish children with tubercu-
losis (TB) than in control cases [32]. In addition, the
prevalence rate of TLR2 2258 SNP was reported to be in-
creased in patients with pulmonary TB alone, as well as
with definitive pulmonary plus extrapulmonary TB, as com-
pared to cases with latent TB infection [32]. In German
adult patients with Candida sepsis, the heterozygotic status
in TLR2 2258 G>A SNP was correlated with altered cyto-
kine release, including increased plasma concentrations of
TNF-α and decreased levels of IFN-γ and IL8 [33]. Consid-
ering genotypic variability in TLR2 2258 locus, it should
also be noticed that some populations, living in Barbados,
the South-Western USA, Bangladesh, China, Nigeria,
Texas, Gambia, Japan, the United Kingdom, Vietnam,
Kenya, Sierra Leone, Los Angeles in the USA, as well as in
Lima, Peru (see http://www.ncbi.nlm.nih.gov/variation/
tools/1000genomes/?q=rs5743708) do not possess the
minor A allele within the reported region. Hence the poly-
morphism, analyzed in this study, can plausibly be involved
in the development of congenital infection with HCMV
only in some populations. Given the previous papers on the
role of TLR2 molecule in the immune response against
HCMV, the altered TLR2 gene in the range of 2258 G>A
SNP may also be involved in the development of congenital
infection with the virus in populations, carrying the minor
allele. Additionally, previous papers from studies, per-
formed in fetuses and neonates, as well as in children with
congenital HCMV infection, also showed some contribu-
tion of other TLR polymorphisms to the occurrence of in-
fection [14, 25]. Our recent study in fetuses and neonates,
with and without congenital HCMV infection, presented
that TLR4 and TLR9 SNPs were associated with the devel-
opment of congenital cytomegaly [14]. Considering the
multiple-SNP analysis, performed in the current study for
TLR2, TLR4 and TLR9 SNPs, a correlation was found be-
tween the presence of AA complex variants for TLR2 2258
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congenital infection. Moreover, among the infected off-
springs, the AA multiple-SNP variants were significantly as-
sociated with higher viral loads, estimated in maternal
blood and urine samples. The observed increased viral
levels in fetal amniotic fluids and maternal urine samples
were also correlated with the occurrence of GA complex
variants for the analyzed TLR2 and TLR9 SNPs among con-
genitally infected fetuses and neonates. Regarding these two
polymorphisms, a previous study, performed for Polish in-
fants with postnatal or unproven congenital HCMV infec-
tion, showed both heterozygotes and recessive
homozygotes in TLR9 -1486 T>C and 2848 G>A SNPs to
be at almost 4-fold increased risk of HCMV disease in an
adjusted model, including HCMV DNA loads [51]. Consid-
ering our outcomes, the common contribution of TLR2
2258 and TLR9 2848 G>A polymorphisms to the develop-
ment of congenital infection seems to be particularly pos-
sible, since TLR9 2848 G>A SNP was also previously
reported to be involved in an increased risk of HCMV in-
fection among fetuses and neonates, although the poly-
morphism is not associated either with amino acid changes
of TLR9 molecule or with alterations of the regulatory site
of TLR9 gene [14, 52]. Hence, the presented data suggest
some role of different TLR molecules, as well as of various
genetic modifications, located within TLR genes, in the oc-
currence of congenital HCMV infection.
Since TLR2 2258 G>A SNP coding Arg753Gln non-
synonymous change is located within a group of highly
conserved amino acids at the C-terminal cytoplasmic Toll-
interleukin 1 receptor domain of the TLR2 molecule, its
contribution to the receptor-induced signal pathways was
reported as plausible [53, 54]. Accordingly to molecular
modeling studies of TLR2 Arg753Gln variation, discrete
main and side chain differences were reported, affecting the
analyzed residue itself [54]. The alteration was suggested to
be associated with interactions between the intracellular
signaling of Toll-IL-1R (TIR) 2 and TIR1 domains [54]. In
addition, the polymorphism was determined to change the
electrostatic potential of the DD loop and αD region, re-
lated to the Arg753Gln polymorphism, causing a slight
movement of the residues, participating in protein-protein
interactions [54]. TLR2 2258 G>A SNP was reported as
correlated with impaired agonist-induced tyrosine phos-
phorylation, heterodimerization of TLR2 with TLR6, and
recruitment of Mal and MyD88 adapter proteins [54]. Out
of them, Myd88 is the key molecule involved in the trans-
mission of TLR2 induced signaling pathways of non-
specific anti-HCMV response [54]. Hence, it is plausible
that TLR2 2258 G>A polymorphism, may be involved in
the occurrence and development of congenital infection
with HCMV through affected TLR2/Myd88 signaling,
caused by altered conformation and the electrostatic poten-
tial of the TIR2 domain [54]. In transfected HEK293cells, treated with Mycobacterium tuberculosis or myco-
bacterial components, the presented signal alterations were
associated with a decreased phosphorylation of p38, NF-κB
activation and IL8 transcription [54]. Another in vitro
study, performed with transfected HEK293 cells, challenged
with a tripalmitoylated hexapeptide (Pam3CSK4), showed
TLR2 2258 G>A SNP to have been associated with a
substantially reduced activity of TLR2, as well as with 50%
decreased activity of the NF-κB-driven reporter gene [55].
In other studies, the heterozygotic status in TLR2 2258
G>A locus was also reported to be associated with the
molecule hypo-responsiveness upon stimulation with the
synthetic TLR2 ligand Pam3CysSK4, as well as reduced
signaling via the TLR2/TLR1-complex [38, 56]. Consider-
ing the previous data on the function of TLR2 and its
2258 G>A polymorphism, in the related signaling path-
ways, as well as the outcomes of our study, we suggest
that, in Polish fetuses and newborns with congenital
HCMV infection, GA heterozygotic status in the analyzed
region may cause hypo-responsiveness of the produced
TLR2 molecule to infection with HCMV. The altered
function of TLR2 may result from impaired heterodimeri-
zation of TLR2 with TLR1 molecule, the affected TLR2/
Myd88 signaling, the changed TLR2-dependent NF-κB
signaling and, in result, the inflammatory cytokine release.
It seems possible that in GA heterozygotes, the presence
of only one correct G allele in TLR2 2258 G>A locus
might be insufficient for complete immune response
against HCMV. Considering all the recently obtained re-
sults for TLR2, TLR4 and TLR9 SNPs, the TLR2 2258
G>A polymorphism seems to be an important genetic fac-
tor, correlated with an increased risk of HCMV congenital
infection among fetuses and neonates. However, further
studies would be justified to investigate in more detail the
molecular mechanism which underlies TLR2 polymorph-
ism involvement in the development of congenital HCMV
infection.
Conclusions
The results of our study demonstrate that TLR2 2258
G>A SNP may be an important genetic factor of the pre-
viously analyzed TLR2, TLR4 and TLR9 polymorphisms,
which is involved in the development of congenital
HCMV infection in Polish fetuses and neonates. The GA
heterozygotic status in the polymorphic region was cor-
related with HCMV infection, increasing 10 times the
risk of the infection and the A allele in TLR2 SNP was
significantly more frequently found among the infected
fetuses and neonates than in the uninfected controls.
Moreover, the occurrence of AA complex variant in the
range of both TLR2 2258 and TLR9 2848 G>A SNPs,
was correlated with an increased risk of the studied con-
genital infection as well. Taking into account the HCMV
DNA loads, significantly higher levels were determined
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variants for the analyzed TLR2 and TLR9 polymor-
phisms, in maternal blood specimens of mothers for the
offsprings of AA complex variants, as well as in maternal
urine samples for the carriers of GA multiple-SNPs.
TLR2 molecule was previously reported to have been
associated with altered immune responses to HCMV,
particularly in triggering the NF-κB activity and the
release of inflammatory cytokines. An in vitro study with
transfected HEK293 cells showed TLR2 2258 G>A SNP
contribution to reduced activity of TLR2 reporter gene.
In case of congenital disease in Polish fetuses and neo-
nates, the participation of the analyzed TLR2 SNP in the
development of HCMV infection seems to be fairly
plausible through reduced TLR2 activity, impaired het-
erodimerization of TLR2 with TLR1 molecule, affected
TLR2/Myd88 signaling as well as TLR2-dependent NF-
κB molecule. Considering TLR9 2848 G>A SNP, the
polymorphism has recently been determined to be
correlated with an increased risk of congenital HCMV
infection, while it is not associated with any molecular
changes of the regulatory site within TLR9 gene or the
encoded protein. Therefore, the common contribution
of TLR9 2848 G>A, together with TLR2 2258 G>A SNP,
to the occurrence of HCMV infection seems possible.
Further research would be beneficial with detailed mech-
anistic studies on the role of TLR2 2258 SNP in congeni-
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